People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2022 |
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2025 |
| Bionovo Inc | — | Pharmaceuticals | Pre-Seed | $600K | $28.4M | 2010 |
Mary Tagliaferri at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mary Tagliaferri on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Jishnu Bhattacharjee | 1 | 9 |
| Aaron Royston | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Maha Katabi | 1 | 6 |
| R. Jacob Vogelstein | 1 | 6 |
| Thomas Miller | 1 | 5 |
| Shalini Sharp | 1 | 4 |
| William Rastetter | 1 | 4 |
| Isaac Cohen | 1 | 3 |
| Thomas C. Chesterman | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Ken Song | 1 | 2 |
| Arvind Kush | 1 | 2 |
| Angie You | 1 | 2 |
| Deborah Charych | 1 | 2 |
| Alex Rosen | 1 | 2 |
| John C. Baxter | 1 | 1 |
| Fred Manby | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.